Optical Disorders Drugs Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Optical Disorders Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Prescription Type (Over-The-Counter Drugs, Prescription Ophthalmic Drugs), By Therapeutics (Age-Related Macular Degeneration, Conjunctivitis, Diabetic Macular Edema, Diabetic Retinopathy, Dry Eye, Eye Cancer, Glaucoma, Others), By End User (Diagnostic Centers, Eye Clinics, Hospitals), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Optical Disorders Drugs Market is projected to experience substantial growth, expanding from USD 23.88 Billion in 2025 to USD 51.24 Billion by 2031, at a CAGR of 13.57%. This market encompasses pharmaceutical agents developed to treat various ocular pathologies, including glaucoma, age-related macular degeneration, and diabetic retinopathy, by mechanisms such as intraocular pressure regulation, angiogenesis inhibition, or inflammation reduction to preserve vision. The market's expansion is largely driven by a globally aging population and the increasing prevalence of chronic lifestyle diseases, like diabetes, which significantly raise the incidence of retinal conditions. Furthermore, improved diagnostic infrastructure in developing nations is progressively enhancing patient access to essential ophthalmic care. Despite this potential, the high cost of novel biologic therapies continues to impede market growth, often limiting access in lower-income regions. In 2025, an estimated 1.1 billion people worldwide lived with sight loss, highlighting a critical need for affordable therapeutic solutions, yet stringent reimbursement policies and insufficient healthcare funding challenge the broad adoption of premium ocular drugs.
Market Driver
The escalating global incidence of diabetic retinopathy and other lifestyle-related disorders serves as a primary driver for the optical disorders drugs market. Sedentary lifestyles contribute to metabolic conditions, leading to a significant increase in retinal complications requiring pharmacological intervention. For example, in 2020, approximately 1.07 million people globally were blind due to diabetic retinopathy, necessitating continuous anti-VEGF therapies to prevent irreversible vision loss. This growing patient pool underscores the immense commercial opportunity, as evidenced by the Eylea franchise's global net sales totaling $9.38 billion in 2023. Additionally, advancements in ocular drug delivery systems and novel ophthalmic biologics are further propelling market expansion. Innovation is shifting towards sustained-release technologies and bispecific antibodies, which extend treatment intervals and improve patient compliance compared to traditional monthly injections. This trend, exemplified by the $2.4 billion in sales for the bispecific antibody Vabysmo in 2023, enhances clinical outcomes and supports premium pricing strategies, thereby bolstering overall market revenue.
Market Challenge
The high cost of novel biologic therapies represents a significant obstacle to the commercial expansion of the Global Optical Disorders Drugs Market. Although these premium agents demonstrate clinical efficacy for conditions such as wet age-related macular degeneration and diabetic macular edema, their pricing structures frequently exceed the financial capacity of healthcare systems and individual payers. Consequently, strict reimbursement policies and limited funding availability compel healthcare providers to prioritize cost containment over clinical preference, thereby restricting the adoption of branded therapeutics. This financial pressure often leads physicians to opt for cheaper, off-label alternatives or delay necessary treatments, which directly diminishes the market share of approved, higher-priced drugs. The impact of these economic constraints is evident in industry data, with approximately 93% of surveyed retina specialists in 2025 reporting switches to lower-cost therapeutic alternatives due to unreliable copay assistance and funding shortages. Such shifts not only reduce revenue trajectories for manufacturers of proprietary biologic drugs but also underscore the market's susceptibility to pricing sensitivities, indicating that without sustainable reimbursement models, the growth potential of advanced ocular therapies will remain constrained by affordability barriers.
Market Trends
The commercialization of complement inhibitors for geographic atrophy (GA) marks a transformative shift in the market, establishing a new therapeutic segment for this previously untreatable advanced form of dry age-related macular degeneration. Unlike standard anti-VEGF agents that target angiogenesis in wet AMD, these novel therapeutics regulate the overactivation of the complement cascade to slow the expansion of retinal lesions. The rapid clinical uptake of these first-in-class C3 and C5 inhibitors highlights the urgent demand for treatments capable of preserving visual function in non-exudative conditions. The strong market entry is validated by Apellis Pharmaceuticals reporting U.S. net product revenue of $150.9 million for its GA therapy, Syfovre, in Q3 2025. Simultaneously, the expansion of gene therapy pipelines is advancing the development of one-time curative interventions for inherited retinal disorders and chronic vascular retinopathies. Pharmaceutical companies are increasingly utilizing adeno-associated virus (AAV) vectors to deliver functional genetic material directly to retinal cells, aiming for durable efficacy that overcomes the limitations of chronic monthly injections. This strategic focus involves substantial capital investment into late-stage clinical trials to establish genetic medicines as viable foundations for treating conditions like wet AMD and diabetic macular edema, as demonstrated by 4D Molecular Therapeutics' reported cash position of $417 million to fund accelerated Phase 3 development of its intravitreal genetic medicine, 4D-150, in Q2 2025.
Key Market Players
* Novartis AG
* F. Hoffmann-La Roche Ltd.
* Pfizer Inc.
* Johnson & Johnson
* AbbVie Inc.
* Bayer AG
* Regeneron Pharmaceuticals, Inc.
* Alcon Inc.
* Bausch Health Companies Inc.
* Santen Pharmaceutical Co., Ltd.
Report Scope
In this report, the Global Optical Disorders Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Optical Disorders Drugs Market, By Prescription Type
* Over-The-Counter Drugs
* Prescription Ophthalmic Drugs
# Optical Disorders Drugs Market, By Therapeutics
* Age-Related Macular Degeneration
* Conjunctivitis
* Diabetic Macular Edema
* Diabetic Retinopathy
* Dry Eye
* Eye Cancer
* Glaucoma
* Others
# Optical Disorders Drugs Market, By End User
* Diagnostic Centers
* Eye Clinics
* Hospitals
# Optical Disorders Drugs Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Optical Disorders Drugs Market.
Available Customizations:
Global Optical Disorders Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Optical Disorders Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Prescription Type (Over-The-Counter Drugs, Prescription Ophthalmic Drugs)
5.2.2. By Therapeutics (Age-Related Macular Degeneration, Conjunctivitis, Diabetic Macular Edema, Diabetic Retinopathy, Dry Eye, Eye Cancer, Glaucoma, Others)
5.2.3. By End User (Diagnostic Centers, Eye Clinics, Hospitals)
5.2.4. By Region
5.2.5. By Company (2025)
5.3. Market Map
6. North America Optical Disorders Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Prescription Type
6.2.2. By Therapeutics
6.2.3. By End User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Optical Disorders Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Prescription Type
6.3.1.2.2. By Therapeutics
6.3.1.2.3. By End User
6.3.2. Canada Optical Disorders Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Prescription Type
6.3.2.2.2. By Therapeutics
6.3.2.2.3. By End User
6.3.3. Mexico Optical Disorders Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Prescription Type
6.3.3.2.2. By Therapeutics
6.3.3.2.3. By End User
7. Europe Optical Disorders Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Prescription Type
7.2.2. By Therapeutics
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Optical Disorders Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Prescription Type
7.3.1.2.2. By Therapeutics
7.3.1.2.3. By End User
7.3.2. France Optical Disorders Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Prescription Type
7.3.2.2.2. By Therapeutics
7.3.2.2.3. By End User
7.3.3. United Kingdom Optical Disorders Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Prescription Type
7.3.3.2.2. By Therapeutics
7.3.3.2.3. By End User
7.3.4. Italy Optical Disorders Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Prescription Type
7.3.4.2.2. By Therapeutics
7.3.4.2.3. By End User
7.3.5. Spain Optical Disorders Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Prescription Type
7.3.5.2.2. By Therapeutics
7.3.5.2.3. By End User
8. Asia Pacific Optical Disorders Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Prescription Type
8.2.2. By Therapeutics
8.2.3. By End User
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Optical Disorders Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Prescription Type
8.3.1.2.2. By Therapeutics
8.3.1.2.3. By End User
8.3.2. India Optical Disorders Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Prescription Type
8.3.2.2.2. By Therapeutics
8.3.2.2.3. By End User
8.3.3. Japan Optical Disorders Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Prescription Type
8.3.3.2.2. By Therapeutics
8.3.3.2.3. By End User
8.3.4. South Korea Optical Disorders Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Prescription Type
8.3.4.2.2. By Therapeutics
8.3.4.2.3. By End User
8.3.5. Australia Optical Disorders Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Prescription Type
8.3.5.2.2. By Therapeutics
8.3.5.2.3. By End User
9. Middle East & Africa Optical Disorders Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Prescription Type
9.2.2. By Therapeutics
9.2.3. By End User
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Optical Disorders Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Prescription Type
9.3.1.2.2. By Therapeutics
9.3.1.2.3. By End User
9.3.2. UAE Optical Disorders Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Prescription Type
9.3.2.2.2. By Therapeutics
9.3.2.2.3. By End User
9.3.3. South Africa Optical Disorders Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Prescription Type
9.3.3.2.2. By Therapeutics
9.3.3.2.3. By End User
10. South America Optical Disorders Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Prescription Type
10.2.2. By Therapeutics
10.2.3. By End User
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Optical Disorders Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Prescription Type
10.3.1.2.2. By Therapeutics
10.3.1.2.3. By End User
10.3.2. Colombia Optical Disorders Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Prescription Type
10.3.2.2.2. By Therapeutics
10.3.2.2.3. By End User
10.3.3. Argentina Optical Disorders Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Prescription Type
10.3.3.2.2. By Therapeutics
10.3.3.2.3. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Optical Disorders Drugs Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Novartis AG
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. F. Hoffmann-La Roche Ltd.
15.3. Pfizer Inc.
15.4. Johnson & Johnson
15.5. AbbVie Inc.
15.6. Bayer AG
15.7. Regeneron Pharmaceuticals, Inc.
15.8. Alcon Inc.
15.9. Bausch Health Companies Inc.
15.10. Santen Pharmaceutical Co., Ltd.
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們